A 3 Years Naturalistic Cohort Survey Of Virtue® Male Sling System For Male Stress Urinary Incontinence

Urinary Incontinence, Stress Clinical Trial

Official title:

A 3 Years Naturalistic Cohort Survey Of Virtue® Male Sling System For Male Stress Urinary Incontinence A Post-marketing and Multicenter Prospective Observational Cohort in Subjects With Male Stress Urinary Incontinence

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04098822
• Other study ID #: SU018
• Status: Recruiting
• Start date: June 29, 2017
• Est. completion date: December 2026

Study information

• Verified date: February 2023
• Source: Coloplast A/S
• Contact: Hugo Ryckebusch, Dr
• Phone: +33 1 40 83 68 52
• Email: frhr[@]coloplast.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to monitor the use of Virtue® Male Sling in a real world population and collect medical data on effectiveness and to monitor safety of Virtue® at 12 and 36 months post device implantation in men with post-prostatectomy urinary incontinence.

Description:

This project will be launched after the first introduction of Virtue® Male Sling in Europe. This study is a multicenter prospective, non-interventional (i.e. naturalistic) post-marketing clinical follow up of men with urinary incontinence implanted with Virtue® Male Sling System by urologists who are experienced in the device. The patient will be followed for 12 months in routine real world clinical practice except for administration of subject questionnaire(s). Routine visits will be performed approximately at baseline (preoperative and implantation period), between 1 and 3 months (immediate post-operative period) and 12 months. Then questionnaires will be mailed annually during 2 additional years.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 130
• Est. completion date: December 2026
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Implanted with the Virtue® Male Sling System

Exclusion Criteria:

• Refuses to be included in the survey or that their medical data will be used for research purposes.

• Indication for the Virtue® Male Sling System implantation is not for the treatment of male urinary incontinence

Related Conditions & MeSH terms

• Enuresis
• Urinary Incontinence
• Urinary Incontinence, Stress

Intervention

Device:
• Virtue male sling
The Coloplast Virtue® Male Sling is a Class II, implantable, sub-urethral, permanent, non-absorbable support sling indicated for the surgical treatment of male SUI resulting from in-trinsic sphincter deficiency (ISD). The sling is manufactured from polypropylene and is sold for single use only. The device is a quadratic sling and consists of a knitted monofilament polypropylene mesh. The body of the device provides surface area for supporting the bulbous urethra.

Locations

Country	Name	City	State
France	CHU Angers	Angers
France	Jean Minjoz Hospital	Besançon
France	CHU de Caen	Caen
France	Centre Hospitalier Chalon Sur Saône William Morey	Chalon-sur-Saône
France	Groupe Hospitalier Henri Mendor	Créteil
France	Claude Huriez Hospital	Lille
France	Clinique Mutualiste de la Porte de l'Orient	Lorient
France	Edouard Herriot Hospital	Lyon
France	Clinique de l'Esperance	Mougins
France	CHU Carémeau	Nîmes
France	Clinique Urologique Nantes-Atlantis	Saint-Herblain
France	Clinique Paul Picquet	Sens
Italy	Ospedale Generale Regionale F. Miull	Acquaviva Delle Fonti

Sponsors (1)

Lead Sponsor	Collaborator
Coloplast A/S

Countries where clinical trial is conducted

France,  Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Patient Global Impression of Improvement (PGI-I)	PGI-I is a validated questionnaire that collects the patient's impression of improvement after the surgery. Among this 7-point scale (very much better, much better, a little better, no change, a little worse, much worse and very much worse), we ask the patients to check the one number that best decribes how their urinary tract condition is now, compared with how it's was before the surgery. Patients who score little or much or very much better will be considered a treatment success. We measure the percentage of patient who describe the treatment success	12 months
Primary	Adverse events	Adverse events are any untoward medical occurrence, unintended disease or injury or any untoward clinical signs in subjects. Adverse events will be categorized according to relatedness to device or procedure, severity, and frequency. At 12-months, we measure the percentage of patients without any device related severe or serious adverse events.	12 months
Secondary	Pad weight testing	Percent change in weight from baseline in 24-hour or 1-hour pad weight test	Baseline, 8 weeks and 12 months
Secondary	Uroflowmetry	Uroflowmetry including a measure of voided volume and the peak urine flow rate (Qmax) will be collected up to 12-months. Data will be used to determine the presence of urinary obstruction. If the Qmax is considered normal by the physician after the procedure it is not necessary to collect these data at subsequent follow-up visits.	Baseline, 8 weeks, 12 months
Secondary	Post-void residual (PVR) volume	PVR volume will be collected pre-and post implant procedure up to 12-months. If the PVR volume is considered normal by the physician after the procedure it is not necessary to collect these data at subsequent follow-up visits.	Baseline, 8 weeks, 12 months
Secondary	Pad Use	The number of pads used per day will be collected. Patients will be considered to be pad free if they report never wearing pads or wear pads just for a sense of security.	Baseline, 8 weeks, 12, 24, 36 months
Secondary	International Consultation on Incontinence Questionnaire (ICIQ-UI)	The ICIQ-UI Short Form is a self-administred questionnaire to evaluate the frequency, severity, and impact on quality of life of urinary incontinence. Question 1 asked, "How often do you leak urine?" Subjects were instructed to select among "none" (0), "about once a week or less often" (1), "2 or 3 times a week" (2), "about once a day" (3), "several times a day" (4), and "all the time" (5). Question 2 asked, "How much urine do you usually leak (whether you wear protection or not)?" Patients responded with "none" (0), "a small amount" (2), "a moderate amount" (4) or "a large amount (6). Question 3 asked, "Overall, how much does leaking urine interfere with your everyday life?" Participants chose a number from 0 (not at all) to 10 (a great deal). Questions 1, 2 and 3 are summed to compute the total ICIQ SF score. The total score range is then a minimum of 0 to a maximum of 21. The mean score, absolute and relative change compared to baseline will be measure	Baseline, 8 weeks, 12, 24, 36 months
Secondary	Subject global satisfaction questionnaire	This non-validated questionnaire provides additional information concerning patient satisfaction. The survey consists of two questions: How satisfied are you with your surgery?. Among 5 point-scale (very satisfied, satisfied, not satisfied-not dissatisfied, dissatisfied, very dissatisfied), patient check the one item that best describes the subject satisfaction. We measure the percentage the patients who very satisfied and satisfied. The patient answer the question "Do you recommend this operation to a friend?" by yes or no. We measure the percentage the patients who answer "yes".	8 weeks, 12, 24, 36 months
Secondary	Incontinence quality of life questionnaire (I-QoL)	The I-QoL is a validated survey questionnaire with 22 items that are scored on a 5-point Likert scale. The I-QOL and its subscale scores are computed by adding each item's response, subtracting the lowest possible score and dividing that sum by the possible raw score range. The scores are then transformed to have a range from 0 (maximum problem) to 100 (no problem at all). The mean score, absolute and relative change compared to baseline	Baseline, 8 weeks, 12, 24, 36 months